Developments Myovant Sciences completes recruitment for Phase 3 endometriosis study Myovant Sciences (NASDAQ:MYOV) completed patient recruitment for its first of two Phase 3 studies of relugolix combination therapy for the treatment of endometriosis-associated pain. Relugolix is a once daily, oral... August 20, 2019